Companies › Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tulisokibart (MK-7240/PRA023) IL-18 receptor antagonist | IL-18R1 | Phase 2 | Diffuse Cutaneous Systemic Sclerosis | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05270668 | Tulisokibart (MK-7240/PRA023) | Phase 2 | Diffuse Cutaneous Systemic Sclerosis | Immunology | Nov 2026 |
–
RAPT Therapeutics, Inc., a member of the GSK plc group of companies AnaptysBio Q32 Bio Chengdu Kangnuoxing Biopharma Ashibio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.